Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines

References

• World Health Organization (WHO). Global burden of stroke. In: The Atlas of Heart Disease and Stroke. Available from http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_ burden_stroke.pdf [Last accessed 10 October 2006]
   Google Scholar
• Kleindorfer D, Panagos P, Pancioli A, et al. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 2005;36:720–4
   PubMed Web of Science ®Google Scholar
• Coull AJ, Lovett JK, Rothwell PM, et al. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organization of services. BMJ 2004;328:326
   PubMed Web of Science ®Google Scholar
• Johnston SC, Gress DR, Browner WS, et al. Short-term prognosis after emergency department diagnosis of transient ischemic attack. JAMA 2000;284:2901–6
   PubMed Web of Science ®Google Scholar
• Hankey GJ. Redefining risks after TIA and minor ischaemic stroke. Lancet 2005;365:2065–6
   PubMed Web of Science ®Google Scholar
• Johnston SC. Transient ischemic attacks are emergencies. Stroke 2005;36:724
   PubMed Web of Science ®Google Scholar
• Brown DL, Lisabeth LD, Roychoudhury C, et al. Recurrent stroke risk is higher than cardiac event risk after initial stroke/ transient ischemic attack. Stroke 2005;36:1285–7
   PubMed Web of Science ®Google Scholar
• Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic ischemic disease. Stroke 2002;33:909–16
   Google Scholar
• Van Wijk I, Kappelle LJ, van Gijn J, et al. Long term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet 2005;365:2098–104
   PubMed Web of Science ®Google Scholar
• Clinical guidelines for stroke rehabilitation and recovery. Available from http://www.strokefoundation.com.au [Last accessed 10 October 2006]
   Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86
   PubMed Web of Science ®Google Scholar
• NICE Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events. Available from http://%20www.nice.org.uk/download.aspx?o=TA090guidance [Last accessed 10 October 2006]
   Google Scholar
• Royal College of Physicians. National Clinical Guidelines for Stroke, 2nd edn, 2004. London: Royal College of Physicians. Available from http://www.rcplondon.ac.uk [Last accessed 10 October 2006]
   Google Scholar
• Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999;66:255
   PubMed Web of Science ®Google Scholar
• The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261–6
   Google Scholar
• Farrell B, Godwin J, Richards S, et al. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044–54
   PubMed Web of Science ®Google Scholar
• De Schryver ELLM, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD001820. DOI:10.1002/14651858. CD001820.pub2
   Google Scholar
• Leonardi-Bee J, Bath PMW, Bousser MG, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events. A meta-analysis of individual patient data from randomised controlled trials. Stroke 2005;36:162–8
   Google Scholar
• De Schryver ELLM, Algra A, van Gijn J. Dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 2003;34:2072–80
   Google Scholar
• CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–39
   PubMed Web of Science ®Google Scholar
• Hankey GJ. Clopidogrel and thrombotic thrombocytopenic purpura. Lancet 2000 22;356:269–270
   Google Scholar
• Costa J, Ferro JM, Matias-Guiu J, et al. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD004296. DOI:10.1002/14651858.CD004296.pub2
   Google Scholar
• Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double blind, placebo-controlled trial. Lancet 2004;364:331–7
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–17
   PubMed Web of Science ®Google Scholar
• ESPRIT study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 2006;367:1665–73
   PubMed Web of Science ®Google Scholar
• Algra A, Van Gijn J, Algra A, et al. Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone? J Neurol Neurosurg Psychiatry 1999;66:557–9
   PubMed Web of Science ®Google Scholar
• Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neuro Sci 1996;143:1–13
   Google Scholar
• DGN/DSG Primary and Secondary Prevention of Cerebral Ischaemia. Available from http://www.dgn.org/241.0.html [Last accessed 10 October 2006]
   Google Scholar
• Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke 2006;37:577–617
   PubMed Web of Science ®Google Scholar
• Diener HC, Sacco R, Yusuf S. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007;23:368–80
   Google Scholar
• Gebel JM. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient. J Am Coll Cardiol 2005;46:752–5
   PubMed Web of Science ®Google Scholar
• Gebel JM. Secondary stroke prevention and antiplatelet therapy [letter and author reply]. J Am Coll Cardiol 2006;47:2563–70
   PubMedGoogle Scholar
• Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–33
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Burger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288: 2411–20
   PubMed Web of Science ®Google Scholar
• Booze CD, Serebruany VL. The action of dipyridamole to prevent thrombosis: practical implications for the treatment and prevention of stroke. Curr Treat Options Cardiovasc Med 2006;8:221–7
   PubMedGoogle Scholar
• Eisert W. How to get from antiplatelet to antithrombotic treatment. Am J Therapeutics 2001;8:443–9
   PubMedGoogle Scholar
• Juliano L, Pedersen JZ, Rotilio G, et al. A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Radic Biol Med 1995;18:239–47
   PubMed Web of Science ®Google Scholar
• Weyrich SM, Denis MM, Kuhlmann-Eyre JR, et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 2005;111:633–42
   Google Scholar
• Ingerman-Wojenski CM, Silver MJ. Model system to study interaction of platelets with damaged arterial wall. II. Inhibition of smooth muscle cell proliferation by dipyridamole and AHP719. Exp Mol Pathol 1988;48: 116–34
   Google Scholar
• Lindgren A, Husted S, Staaf G, et al. Dipyridamole and headache: a pilot study of initial dose titration. J Neurol Sci 2004;223:179–84
   PubMed Web of Science ®Google Scholar
• Chang YJ, Ryu SJ, Lee TH. Dose titration to reduce dipyridamole-related headache. Cerebrovasc Dis 2006;22:258–62
   Google Scholar
• Neurology Expert Group. Therapeutic guidelines: neurology. Version 3. Melbourne, Australia: Therapeutic Guidelines Limited; 2007 (April)
   Google Scholar